NYU LANGONE HEALTH

Dimerix opens first paediatric site in Mexico for ACTION3 Phase 3 trial of DMX-200 to treat FSGS, with 14 more sites planned across Argentina, US, and UK. Dr Howard Trachtman joins the Medical Advisory Board to support paediatric recruitment. The trial aims to recruit 22 adolescent patients, with DMX-200 dosage confirmed for adolescents. Recruitment for the trial remains on track, with funding secured through various sources.

Sally Lau, MD, discusses her role in the DeLLphi-304 trial, focusing on the accelerated approval of Imdelltra for relapsed small-cell lung cancer. She highlights the importance of nurse navigators and diversity grants in supporting patient enrollment and retention in trials, emphasizing the need for early involvement and responsive sponsors. Lau's passion for clinical trials stems from witnessing direct patient benefits and innovative treatment approaches.

A year after the world's first combined whole-eye and partial face transplant, Aaron James is thriving with no rejection of his new face or eye, though vision has not returned. The surgery, led by Dr. Eduardo Rodriguez, marks a significant step in transplant research, with the transplanted eye maintaining normal pressure and blood flow, contrary to animal experiments. Despite the lack of vision, James' quality of life has significantly improved.